OHMONDE
Just inLouis Vuitton’s make-up puts on the Monogram: Ghesquière and McGrath’s Dune and InfrarougeMulberry: sales up 18%, a £33 million loss — and why both are trueLamborghini’s Temerario Spyder: the first raging bull with a folding hard roofLa Madrague: Brigitte Bardot’s house on the bay of CanoubiersThe New Year editions: Damien Hirst’s Dom Pérignon, Rémy Martin’s centaur and a countdown for the Sun KingThe advent calendars of winter 2026: from YSL’s $400 chest to Dior’s $8,200 trunkLOEWE × Tim Burton: The Nightmare Before Christmas, from a $320 perfume to bags from $8,950Anthropic prices the largest IPO on record — $81 billion, and trading starts todayThe rounds Wall Street is talking about: OpenAI at $1.25 trillion — and four more billion-dollar betsHow to find investors for a startup — from the first cheque to Series AJust inLouis Vuitton’s make-up puts on the Monogram: Ghesquière and McGrath’s Dune and InfrarougeMulberry: sales up 18%, a £33 million loss — and why both are trueLamborghini’s Temerario Spyder: the first raging bull with a folding hard roofLa Madrague: Brigitte Bardot’s house on the bay of CanoubiersThe New Year editions: Damien Hirst’s Dom Pérignon, Rémy Martin’s centaur and a countdown for the Sun KingThe advent calendars of winter 2026: from YSL’s $400 chest to Dior’s $8,200 trunkLOEWE × Tim Burton: The Nightmare Before Christmas, from a $320 perfume to bags from $8,950Anthropic prices the largest IPO on record — $81 billion, and trading starts todayThe rounds Wall Street is talking about: OpenAI at $1.25 trillion — and four more billion-dollar betsHow to find investors for a startup — from the first cheque to Series A
Health · Medicine — Rahway, New Jersey · Cambridge, Massachusetts
by Ohmonde Health Desk
19 August 2026
English / Русский

A personalised mRNA cancer vaccine succeeds in a phase 3 trialПерсонализированная мРНК-вакцина против рака успешно прошла III фазу

Merck and Moderna’s intismeran, given with Keytruda after melanoma surgery, cut the risk of recurrence or death by 42%.Интисмеран от Merck и Moderna вместе с Keytruda после операции по удалению меланомы снизил риск рецидива или смерти на 42%.

A personalised mRNA cancer vaccine succeeds in a phase 3 trial
Illustrative · ThisisEngineering · Unsplash

Merck and Moderna reported on 19 August 2026 that their phase 3 trial INTerpath-001 met its main goal. In 1,137 patients with completely removed high-risk (stage IIB–IV) melanoma, intismeran — a vaccine made individually for each patient’s tumour — given with the immunotherapy Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone, at a median follow-up of 24.6 months. It also improved survival free of distant metastases.

It is the first positive phase 3 result for an individualised neoantigen therapy and for any mRNA-based cancer treatment. Regulators have not yet approved it; full data and longer follow-up will decide how far it goes.

19 августа 2026 года Merck и Moderna сообщили, что исследование III фазы INTerpath-001 достигло основной цели. У 1137 пациентов с полностью удалённой меланомой высокого риска (стадии IIB–IV) интисмеран — вакцина, которую создают индивидуально под опухоль каждого пациента, — вместе с иммунотерапией Keytruda снизил риск рецидива или смерти на 42% по сравнению с одной Keytruda при медиане наблюдения 24,6 месяца. Улучшилась и выживаемость без отдалённых метастазов.

Это первый положительный результат III фазы для индивидуальной неоантигенной терапии и для любого лечения рака на основе мРНК. Регуляторы препарат пока не одобрили; дальнейшее решат полные данные и более долгое наблюдение.

SourcesИсточники

  1. CancerNetwork — cancer vaccine meets endpoints in resected melanoma
  2. AJMC — Merck, Moderna vaccine cuts melanoma recurrence risk by 42%

OHMONDE writes its stories in its own words from the sources above. Spotted an error? hello@ohmonde.com

Read nextЧитайте также